Loading
A phase 2 trial of Venetoclax in acute myeloid leukaemia, run by Ryvu Therapeutics SA, now recruiting.
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML is a phase 2 interventional study registered as NCT06191263 by Ryvu Therapeutics SA, with 98 participants planned, started 2024-01-05 and due to reach its primary completion in 2027-08. Interventions recorded: RVU120 and Venetoclax.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/